Blog
Abstract
Presented at the American Society of Clinical Oncology 2020 (#ASCO20) Virtual Scientific Program, May 29 to May 31, 2020.
Authors
Leigh Boehmer1, Latha Shivakumar1, Christine B. Weldon2, Julia Rachel Trosman3, Stephanie A. Cohen4, Dawn Nixon4, Zohra Ali-Khan Catts5, Susan Miesfeldt6, Stephanie Wiryaman7, Lorraine Tafra8, Lisa Muto9, Natalie Fadrowski10, Melissa Hulvat11, Tiana Pallister11, Charles Hendrix Shelton12
1Association of Cancer Care Centers, Rockville, MD; 2Northwestern University Feinberg School of Medicine, Chicago, IL; 3Center for Business Models in Healthcare, Chicago, IL; 4St. Vincent Hospital, Indianapolis, IN; 5Christiana Care Health System, Newark, DE; 6Maine Medical Ctr Cancer Inst, Scarborough, ME; 7Maine Medical Center, Portland, ME; 8Anne Arundel Medical Ctr, Annapolis, MD; 9Cabell Huntington Hospital, Huntington, WV; 10University of Maryland Upper Chesapeake Health, Bel Air, MD; 11Kalispell Regional Medical Center, Kalispell, MT; 12Vidant Health, Nags Head, NC
Current National Comprehensive Cancer Network® guidelines state that testing for highly penetrant breast/ovarian cancer genes is clinically indicated for women diagnosed with early onset (≤ 45 years), at later age (having met ethnic or family history criteria), or metastatic HER-2 negative breast cancer.
A recent Association of Cancer Care Centers (ACCC) survey (N = 95) showed that > 80% of respondents reported ≤ 50% testing rates among patients with breast cancer who met testing guidelines.
Given this disconnect, ACCC partnered with 15 community cancer programs to assess practice gaps and support interventions to improve genetic counseling/testing access.